ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ELUTIA INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.82+0.02 (+2.67%)

Close on Oct 19, 2026

Market cap: $36.05M
P/E (TTM): 0.9
Dividend yield: –

ELUTIA INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	12	14	25	24	47	43	43
Cost of Revenue	5.70	7.75	14	12	28	22	23
Gross Profit	6.60	6.72	11	12	19	21	20
Research & Development	4.16	3.00	4.40	7.73	9.27	5.95	2.40
Selling, General & Admin	21	23	27	34	33	28	26
Selling & Marketing	5.77	4.99	13	18	19	18	16
General & Administrative	15	18	14	16	14	11	9.62
Operating Expenses	34	37	42	47	42	34	28
Operating Income	-27	-31	-31	-35	-23	-14	-8.41
Interest Expense	–	4.78	5.80	5.12	5.32	5.63	5.38
Other Non-Operating Income	-2.76	1.19	-0.76	4.16	3.58	-2.57	1.88
Gain (Loss) on Sale of Assets	80	0.18	7.53	–	–	–	–
Pretax Income	-16	-45	-41	-36	-25	-22	-12
Income Tax Expense	0.01	0.01	0.03	0.03	0.06	0.03	0.03
Income from Continuing Operations	-16	-45	-41	-36	–	–	–
Income from Discontinued Operations	69	-8.60	3.59	3.29	–	–	–
Net Income incl. Noncontrolling Interests	53	-54	-38	-33	-25	-22	-12
Net Income	53	-54	-38	-33	-25	-22	-12
Net Income to Common	0.05	-0.05	-38	-33	-25	-25	-12
EPS (Basic)(per share)	1.29	-1.86	-2.07	-2.38	-2.38	-8.88	-18.48
EPS (Diluted)(per share)	0.87	-1.86	-2.07	-2.38	-2.38	-8.88	-18.48
Shares Outstanding (Basic, Weighted)(shares)	41	29	18	14	10	2.85	0.65
Shares Outstanding (Diluted, Weighted)(shares)	46	29	18	14	10	2.85	0.65
EBITDA	-24	-27	-27	-31	-19	-9.74	-4.55

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 57.8%
Operating margin: -214.9%
Net margin: 426.9%
Return on equity, FY2025: -574.3%

Financial strength

Current ratio: 1.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 94.5%

Valuation

P/E ratio: 0.9
Price to sales: 2.97
Price to book: 2.29
Dividend yield: –